Unknown

Dataset Information

0

Characterization of interaction between blood coagulation factor VIII and LRP1 suggests dynamic binding by alternating complex contacts.


ABSTRACT:

Background

Deficiency in blood coagulation factor VIII (FVIII) results in life-threating bleeding (hemophilia A) treated by infusions of FVIII concentrates. To improve disease treatment, FVIII has been modified to increase its plasma half-life, which requires understanding mechanisms of FVIII catabolism. An important catabolic actor is hepatic low density lipoprotein receptor-related protein 1 (LRP1), which also regulates many other clinically significant processes. Previous studies showed complexity of FVIII site for binding LRP1.

Objectives

To characterize binding sites between FVIII and LRP1 and suggest a model of the interaction.

Methods

A series of recombinant ligand-binding complement-type repeat (CR) fragments of LRP1 including mutated variants was generated in a baculovirus system and tested for FVIII interaction using surface plasmon resonance, tissue culture model, hydrogen-deuterium exchange mass spectrometry, and in silico.

Results

Multiple CR doublets within LRP1 clusters II and IV were identified as alternative FVIII-binding sites. These interactions follow the canonical binding mode providing major binding energy, and additional weak interactions are contributed by adjacent CR domains. A representative CR doublet was shown to have multiple contact sites on FVIII.

Conclusions

FVIII and LRP1 interact via formation of multiple complex contacts involving both canonical and non-canonical binding combinations. We propose that FVIII-LRP1 interaction occurs via switching such alternative binding combinations in a dynamic mode, and that this mechanism is relevant to other ligand interactions of the low-density lipoprotein receptor family members including LRP1.

SUBMITTER: Chun H 

PROVIDER: S-EPMC9804390 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background</h4>Deficiency in blood coagulation factor VIII (FVIII) results in life-threating bleeding (hemophilia A) treated by infusions of FVIII concentrates. To improve disease treatment, FVIII has been modified to increase its plasma half-life, which requires understanding mechanisms of FVIII catabolism. An important catabolic actor is hepatic low density lipoprotein receptor-related protein 1 (LRP1), which also regulates many other clinically significant processes. Previous studies show  ...[more]

Similar Datasets

| S-EPMC8160500 | biostudies-literature
| S-EPMC8223065 | biostudies-literature
| S-EPMC1135641 | biostudies-other
| S-EPMC3001592 | biostudies-literature
| S-EPMC4469981 | biostudies-literature
2024-01-17 | GSE230495 | GEO
| S-EPMC9330781 | biostudies-literature
| S-EPMC3828219 | biostudies-literature
| S-EPMC3724656 | biostudies-literature
2019-01-05 | GSE124663 | GEO